First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 study in RYBREVANT® clinical program

Related Keywords

United States ,Toronto ,Ontario ,Canada ,Chicago ,Illinois ,American ,Prnewswire Johnson ,Natashab Leighl ,Johnson ,None Of Janssen Research Development ,Janssen Research Development ,Janssen Biotech Inc ,Princess Margaret Cancer Centre ,American Society Of Clinical Oncology ,Exchange Commission ,European Medicines Agency ,Clinical Oncology ,Annual Meeting ,Biologics License Application ,New Drug Application ,Priority Review ,Practice Guidelines ,Single Agent ,Prescribing Informationfor ,Innovative Medicine ,Janssen Research ,Janssen Biotech ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,